Part, Chapter, Paragraph
1 II, 5. 4. 1| and failure of different organs, especially eyes, kidneys,
2 II, 5. 9. FB| different reactions in several organs and tissues. Allergy has
3 II, 5. 11. 3| and cancer of internal organs which may be associated
4 II, 9. 1. 2| The development of the organs occurs in the first trimester
5 II, 9. 3. 1| process that affects all organs and systems. The symptoms
6 III, 10. 2. 5| of functional reserves of organs and apparatuses and the
7 III, 10. 3. 3| lungs as well as many other organs; it is most commonly acquired
8 IV, 11. 5. 1| therapies. The use of human organs for transplantation has
9 IV, 11. 5. 1| for end-stage failure of organs such as the liver, lung
10 IV, 11. 5. 1| Every year, a number of organs are exchanged between EU
11 IV, 11. 5. 1| limited availability of organs, the balance between risks
12 IV, 11. 5. 1| constraints due to ischemia of organs. Despite these limitations
13 IV, 11. 5. 3| Exchanges and import/export of organs in different European countries~
14 IV, 11. 5. 3| 11.17. Tumour markers in organs transplants number of countries~ ~
15 IV, 11. 5. 3| procedures for the retrieval of organs, their packaging, labelling,
16 IV, 11. 5. 4| transplantation of humans organs by organized criminal groups.~ ~
17 IV, 11. 5. 4| disparity between the demand for organs and the current supply is
18 IV, 11. 5. 4| number of available cadaveric organs has remained essentially
19 IV, 11. 5. 4| consequences of the scarcity of organs for transplant is trafficking
20 IV, 11. 5. 4| is trafficking of human organs by organized criminal groups.~ ~
21 IV, 11. 5. 4| poor countries to receive organs from poor donors. Since
22 IV, 11. 5. 4| efficiency in the procurement of organs and improved the functioning
23 IV, 11. 5. 4| themselves ready to donate their organs to an organ donation service
24 IV, 11. 5. 4| Family refusals to donate organs of their deceased relatives
25 IV, 11. 5. 4| and willingness to donate organs.~The creation of a European
26 IV, 11. 5. 4| of the holder to donate organs or not, will contribute
27 IV, 11. 5. 4| people willing to donate organs after their death. In spite
28 IV, 11. 5. 4| place ensuring that the organs of people willing to donate
29 IV, 11. 5. 4| viability). In addition, for organs to be transplanted the donor
30 IV, 11. 5. 4| account the short time that organs can be maintained and the
31 IV, 11. 5. 4| the quality and safety of organs. Pre-transplant evaluation
32 IV, 11. 5. 4| effective transportation of organs must be guaranteed in order
33 IV, 11. 5. 4| safety requirements for organs shall complement and be
34 IV, 11. 5. 5| delivering information on organs, tissues and cells to professional
35 IV, 11. 5. 6| tissues and cells, human organs and blood used in medical
36 IV, 11. 5. 6| the quality and safety of organs could be envisaged in the
37 IV, 11. 5. 6| of a European registry on organs, cells and tissues through
38 IV, 11. 5. 6| to tolerate transplanted organs.~Council of Europe~ ~In
39 IV, 11. 5. 6| on quality assurance for organs, tissues and cells and drew
40 IV, 11. 5. 6| and Quality Assurance for Organs, Tissues and Cells” in February
41 IV, 11. 5. 6| Assembly on trafficking in organs in Europe~2003State on~2001Recom )5
42 IV, 11. 5. 6| Procurement and sharing of organs for highly immunised recipients~ –
43 IV, 11. 5. 6| the purchase and sale of organs of human origin~ ~Transplantation
44 IV, 11. 5. 7| that reduce the demand for organs may have an important effect.~ ~ ~
45 IV, 12. 1 | of quality and safety of organs and substances of human
46 IV, 12. 1 | donation or medical use of organs and blood.~ ~Art. 153 “The
47 IV, 12. 5 | the safety and quality of organs and substances of human
